基于导管的肾动脉去神经术治疗难治性高血压的长期结局:随机SYMPLICITY HTN-3试验的最终随访
SYMPLICITY HTN-3试验在88个美国中心随机分配535例难治性高血压患者(2:1)接受肾动脉去神经术或假手术对照。36个月随访显示,去神经术组诊室收缩压变化为-26.4 mm Hg,假手术组为-5.7 mm Hg,校正治疗差异为-22.1 mm Hg(95%CI -27.2至-17.0;p≤0.0001),安全性终点两组相似。
要点
- 去神经术组36个月诊室收缩压较基线降低26.4 mm Hg,假手术组降低5.7 mm Hg(校正差异-22.1 mm Hg,p≤0.0001)。
- 去神经术组36个月24小时动态收缩压降低15.6 mm Hg,假手术组降低0.3 mm Hg(校正差异-16.5 mm Hg,p≤0.0001)。
- 去神经术组血压达标时间比例为18%,假手术组为9%(p≤0.0001),药物负担相似。
核心结论
- 肾动脉去神经术至术后36个月的安全性证据得到补充。
- 从术后12个月至36个月,原随机分配至去神经术组的患者血压降幅大于假手术对照组且血压控制更优。
研究设计与样本
- 单盲、多中心、假手术对照、随机临床试验,在美国88个中心开展。
- 纳入18-80岁难治性高血压患者,需稳定使用最大耐受剂量至少三种降压药(包括利尿剂),诊室收缩压≥160 mm Hg且24小时动态收缩压≥135 mm Hg。
- 共筛查1442例患者,随机分配535例(37%;210例[39%]女性,325例[61%]男性;平均年龄57.9岁[SD 10.7]):364例(68%)接受肾动脉去神经术(平均年龄57.9岁[10.4]),171例(32%)接受假手术对照(平均年龄56.2岁[11.2])。
- 随机分配比例2:1,使用单电极(Flex)导管进行肾动脉去神经术。
- 主要终点为6个月时诊室收缩压自基线的变化,去神经术组与假手术对照组比较。
主要发现
- 36个月时诊室收缩压变化:去神经术组-26.4 mm Hg(SD 25.9),假手术对照组-5.7 mm Hg(SD 24.4);校正治疗差异-22.1 mm Hg(95%CI -27.2至-17.0;p≤0.0001)。
- 36个月时24小时动态收缩压变化:去神经术组-15.6 mm Hg(SD 20.8),假手术对照组-0.3 mm Hg(SD 15.1);校正治疗差异-16.5 mm Hg(95%CI -20.5至-12.5;p≤0.0001)。
- 无插补分析中,去神经术组血压达标时间比例为18%(SD 25.0),假手术对照组为9%(SD 18.8)(p≤0.0001),药物负担相似,插补后结果一致且显著。
- 不良事件发生率在治疗组间相似,无肾动脉去神经术晚期并发症的证据。
- 至48个月复合安全性终点(包括全因死亡、新发终末期肾病、导致终末器官损害的显著栓塞事件、血管并发症、肾动脉再干预和高血压急症)发生率:去神经术组15%(54/352),交叉组14%(13/96),非交叉组14%(10/69)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial showed the safety but not efficacy of the Symplicity system (Medtronic, Santa Rosa, CA, USA) at 6 months follow-up in patients with treatment-resistant hypertension. This final report presents the 36-month follow-up results. METHODS: SYMPLICITY HTN-3 was a single-blind, multicentre, sham-controlled, randomised clinical trial, done in 88 centres in the USA. Adults aged 18-80 years, with treatment-resistant hypertension on stable, maximally tolerated doses of three or more drugs including a diuretic, who had a seated office systolic blood pressure of 160 mm Hg or more and 24 h ambulatory systolic blood pressure of 135 mm Hg or more were randomly assigned (2:1) to receive renal artery denervation using the single electrode (Flex) catheter or a sham control. The original primary endpoint was the change in office systolic blood pressure from baseline to 6 months for the renal artery denervation group compared with the sham control group. Patients were unmasked after the primary endpoint assessment at 6 months, at which point eligible patients in the sham control group who met the inclusion criteria (office blood pressure ≥160 mm Hg, 24 h ambulatory systolic blood pressure ≥135 mm Hg, and still prescribed three or more antihypertensive medications) could cross over to receive renal artery denervation. Changes in blood pressure up to 36 months were analysed in patients in the original renal artery denervation group and sham control group, including those who underwent renal artery denervation after 6 months (crossover group) and those who did not (non-crossover group). For comparisons between the renal artery denervation and sham control groups, follow-up blood pressure values were imputed for patients in the crossover group using their most recent pre-crossover masked blood pressure value. We report long-term blood pressure changes in renal artery denervation and sham control groups, and investigate blood pressure control in both groups using time in therapeutic blood pressure range analysis. The primary safety endpoint was the incidence of all-cause mortality, end stage renal disease, significant embolic event, renal artery perforation or dissection requiring intervention, vascular complications, hospitalisation for hypertensive crisis unrelated to non-adherence to medications, or new renal artery stenosis of more than 70% within 6 months. The trial is registered with ClinicalTrials.gov, NCT01418261. FINDINGS: From Sep 29, 2011, to May 6, 2013, 1442 patients were screened, of whom 535 (37%; 210 [39%] women and 325 [61%] men; mean age 57·9 years [SD 10·7]) were randomly assigned: 364 (68%) patients received renal artery denervation (mean age 57·9 years [10·4]) and 171 (32%) received the sham control (mean age 56·2 years [11·2]). 36-month follow-up data were available for 219 patients (original renal artery denervation group), 63 patients (crossover group), and 33 patients (non-crossover group). At 36 months, the change in office systolic blood pressure was -26·4 mm Hg (SD 25·9) in the renal artery denervation group and -5·7 mm Hg (24·4) in the sham control group (adjusted treatment difference -22·1 mm Hg [95% CI -27·2 to -17·0]; p≤0·0001). The change in 24 h ambulatory systolic blood pressure at 36 months was -15·6 mm Hg (SD 20·8) in the renal artery denervation group and -0·3 mm Hg (15·1) in the sham control group (adjusted treatment difference -16·5 mm Hg [95% CI -20·5 to -12·5]; p≤0·0001). Without imputation, the renal artery denervation group spent a significantly longer time in therapeutic blood pressure range (ie, better blood pressure control) than patients in the sham control group (18% [SD 25·0] for the renal artery denervation group vs 9% [SD 18·8] for the sham control group; p≤0·0001) despite a similar medication burden, with consistent and significant results with imputation. Rates of adverse events were similar across treatment groups, with no evidence of late-emerging complications from renal artery denervation. The rate of the composite safety endpoint to 48 months, including all-cause death, new-onset end-stage renal disease, significant embolic event resulting in end-organ damage, vascular complication, renal artery re-intervention, and hypertensive emergency was 15% (54 of 352 patients) for the renal artery denervation group, 14% (13 of 96 patients) for the crossover group, and 14% (10 of 69 patients) for the non-crossover group. INTERPRETATION: This final report of the SYMPLICITY HTN-3 trial adds to the totality of evidence supporting the safety of renal artery denervation to 36 months after the procedure. From 12 months to 36 months after the procedure, patients who were originally randomly assigned to receive renal artery denervation had larger reductions in blood pressure and better blood pressure control compared with patients who received sham control. FUNDING: Medtronic.
引用
- Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022. PMID: 36130612. doi:10.1016/S0140-6736(22)01787-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。